Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128742 | 0.87 | CYP3A4 (0.68) | CYP3A4CYP2C9GPR119SMN1; SMN2HSD17B10 | |
| SCHEMBL4362383 | 0.85 | CYP2C9 (0.55) | CYP3A4CYP2C9GPR119 | |
| SCHEMBL27852879 | 0.83 | CYP3A4 (0.43) | CYP3A4CYP2C9GPR119SMN1; SMN2HSD17B10 | |
| SCHEMBL4355645 | 0.82 | CYP2C9 (0.46) | CYP3A4CYP2C9GPR119SMN1; SMN2HSD17B10 | |
| SCHEMBL1128538 | 0.82 | CYP3A4 (0.53) | CYP3A4GPR119 | |
| SCHEMBL4352336 | 0.79 | CYP3A4 (0.79) | CYP3A4CYP2C9GPR119 | |
| SCHEMBL1449681 | 0.76 | GPR119 (0.45) | CYP2C9GPR119SMN1; SMN2ALDH1A1 | |
| SCHEMBL1449951 | 0.74 | GPR119 (0.44) | CYP2C9GPR119HSD17B10ALDH1A1 | |
| SCHEMBL1450077 | 0.74 | GPR119 (0.44) | CYP2C9GPR119SMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL1128392 | 0.74 | CYP2C9 (0.72) | CYP3A4CYP2C9GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286812-A1 | GPR119 Receptor Agonists | GPR119, GPR27, GPR139 | CYP3A4 1503/4885CYP2C9 917/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.